Citation Impact
Citing Papers
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
2009 Standout
β 2 -Adrenoceptor signaling is required for the development of an asthma phenotype in a murine model
2009
A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signaling
2007 StandoutNobel
Dual Angiotensin Receptor and Neprilysin Inhibition as an Alternative to Angiotensin-Converting Enzyme Inhibition in Patients with Chronic Systolic Heart Failure: Rationale for and Design of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure Trial (PARADIGM-HF)
2013
Baseline Characteristics and Treatment of Patients in Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF)
2014
β-Arrestin-mediated Signaling Regulates Protein Synthesis
2008 StandoutNobel
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
2007
Ventricular remodeling in heart failure and the effect of β-blockade
2004
Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers for Prevention of Type 2 Diabetes
2005
Effect of Beta Blockers, Particularly Carvedilol, on Reducing the Risk of Events After Acute Myocardial Infarction
2006
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
2010 Standout
A view on drug resistance in cancer
2019 StandoutNature
Analysis of Randomized Controlled Trials on the Effect of Magnitude of Heart Rate Reduction on Clinical Outcomes in Patients With Systolic Chronic Heart Failure Receiving Beta-Blockers
2008
Subtype-specific β-adrenoceptor signaling pathways in the heart and their potential clinical implications
2004
Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure
2012
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
β-Arrestin-biased Agonism at the β2-Adrenergic Receptor
2007 StandoutNobel
Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy
2004
Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency
2009 Standout
Percutaneous Repair or Surgery for Mitral Regurgitation
2011 Standout
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?
2003
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Anti–β1-adrenergic receptor antibodies and heart failure: causation, not just correlation
2004 StandoutNobel
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
2009 Standout
Heart Rate Reduction by If-Channel Inhibition and its Potential Role in Heart Failure with Reduced and Preserved Ejection Fraction
2009
A stress response pathway regulates DNA damage through β2-adrenoreceptors and β-arrestin-1
2011 StandoutNatureNobel
Optimal Pharmacologic and Non-pharmacologic Management of Cardiac Transplant Candidates: Approaches to Be Considered Prior to Transplant Evaluation: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidates—2006
2006
2007 Guidelines for the Management of Arterial Hypertension
2007 Standout
The Evolving Landscape of Brain Metastasis
2018
Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor
2010 StandoutNatureNobel
Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)–Added trial
2006
Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction
2004
The structure and function of G-protein-coupled receptors
2009 StandoutNatureNobel
Resting Heart Rate in Cardiovascular Disease
2007 Standout
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
2009 Standout
Growth Differentiation Factor 11 Is a Circulating Factor that Reverses Age-Related Cardiac Hypertrophy
2013 Standout
Treatment of Hypertension in Patients 80 Years of Age or Older
2008 Standout
Emerging concepts and therapeutic implications of β-adrenergic receptor subtype signaling
2005
β-Arrestin1 mediates nicotinic acid–induced flushing, but not its antilipolytic effect, in mice
2009 StandoutNobel
The European Association for the Study of Diabetes
2005
Airway Mucus Function and Dysfunction
2010 Standout
Mechanisms for Insulin Resistance: Common Threads and Missing Links
2012 Standout
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005)
2005 Standout
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
2014 Standout
Structure of a β1-adrenergic G-protein-coupled receptor
2008 StandoutNatureNobel
Use of a Continuous-Flow Device in Patients Awaiting Heart Transplantation
2007 Standout
Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction
2006 Standout
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)
2005
Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT)
2005
The effect of altering heart rate on ventricular function in patients with heart failure treated with β-blockers
2006
Carvedilol's antiarrhythmic properties: Therapeutic implications in patients with left ventricular dysfunction
2005
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
2018
Plasma Brain Natriuretic Peptide-Guided Therapy to Improve Outcome in Heart Failure
2007
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Biomarkers in Heart Failure
2008 Standout
Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure
2005 Standout
The selectivity of β‐adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors
2005
Myocarditis
2009 Standout
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
2010 Standout
Should beta‐blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET
2007
2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation
2011
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation
2011
A Review of Carvedilol Arrhythmia Data in Clinical Trials
2005
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
2005 Standout
Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET)
2007
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Distinct conformational changes in β-arrestin report biased agonism at seven-transmembrane receptors
2008 StandoutNobel
AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update
2011
2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009
Systems analysis of PKA-mediated phosphorylation gradients in live cardiac myocytes
2006 StandoutNobel
The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes
2006
Meta-analysis: β-Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure
2009
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2006 Standout
Nebivolol
2006
Phosphodiesterase 4D is required for β 2 adrenoceptor subtype-specific signaling in cardiac myocytes
2005 StandoutNobel
Ischemic Mitral Regurgitation on the Threshold of a Solution
2005
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary
2006
Anti–β1-adrenergic receptor antibodies and heart failure: causation, not just correlation
2004 StandoutNobel
Nebivolol
2009
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation
2006
Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands
2009 StandoutNobel
The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex
2009 StandoutNobel
AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update
2011
Expert consensus document on ?-adrenergic receptor blockersThe Task Force on Beta-Blockers of the European Society of Cardiology
2004
What Is the Role of β-Adrenergic Signaling in Heart Failure?
2003
Organization of β-adrenoceptor signaling compartments by sympathetic innervation of cardiac myocytes
2007 StandoutNobel
Weekend versus Weekday Admission and Mortality from Myocardial Infarction
2007 Standout
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial
2010 Standout
2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
2013
Works of Beatrix Lutiger being referenced
Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma
2016
Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure—COMET
2005
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial
2003
The Benefits of Early Combination Treatment of Carvedilol and an ACE-Inhibitor in Mild Heart Failure and Left Ventricular Systolic Dysfunction. The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation Trial (CARMEN)
2004
Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial
2005
Tolerability of carvedilol and ACE‐Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE‐Inhibitor Remodelling Mild CHF EvaluatioN)
2004
Should beta-blocker therapy be reduced or withdrawn in patients with worsening heart failure? insights from COMET
2004